Inflammatory Mediators of Alzheimer’s Disease Characterized in a Mouse Model (APP/PS1)
Authors:
- Adrian JordaAJAdrian Jorda
- Kenia Alvarez-GamezKAKenia Alvarez-Gamez
- Ignacio Campo-PalacioICIgnacio Campo-Palacio
- Juan Campos-CamposJCJuan Campos-Campos
- Carlos ColmenaCCCarlos Colmena
- Sandeep Kumar SinghSandeep Kumar Singh
- Maria Jose Chiva MirallesMMMaria Jose Chiva Miralles
- Constanza AldasoroCAConstanza Aldasoro
- Martin AldasoroMAMartin Aldasoro
- Soraya L. VallesSVSoraya L. Valles
Open Access
Abstract
Alzheimer’s disease (AD) is marked by amyloid plaques, hyperphosphorylated TAU proteins, and neuroinflammation. The APP/PS1 mouse model is widely used to study AD pathogenesis. In this study, we investigated the expression of chemokines and their receptors, which may play a role in AD’s pathological mechanisms, using brain cortex tissue from female APP/PS1 mice aged 20–21 months. We analyzed several chemokine receptors (CCR1, CCR2, CCR3, CCR4, CCR6, CCR7, CCR9, and CCR10) by Western blot and focused on CCR6, CCR7, and CCR10 using RT-PCR. Additionally, we quantified the levels of chemokines (CCL6, CCL8, CCL19, CCL20, CCL24, and CCL27) by RT-PCR. Our results showed a significant decrease in CCL8 and CCL19, along with their respective receptors, in the APP/PS1 mice compared to controls. On the other hand, we observed a notable increase in CCL6, CCL24, CCL20, CCL27, and their receptors. Chemokines like CCL8 and CCL20, involved in inflammatory responses, may reveal how neuroinflammation contributes to AD. CCL19 and CCL27 are linked to immune cell trafficking, which may help explain immune cell interactions with amyloid plaques and TAU tangles in the CNS. Overall, the altered expression of chemokines such as CCL24 could serve as biomarkers for early AD detection and monitoring disease progression. These findings suggest potential therapeutic targets to modulate immune responses and reduce neuroinflammation in AD.Keywords
Funding Information
- Conselleria D’educació, Cultura, Universitats I Ocupació. Direcció General de Ciència i investigación. Generalitat Valenciana (CIAICO/2023/143)
This publication has 72 references indexed in Scilit:
- CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approachesClinical and Translational Oncology, 2025
- Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and TherapeuticsInflammation, 2022
- Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer’s DiseaseMolecular Neurobiology, 2016
- Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkersBiochemical Pharmacology, 2014
- Effects of chemokine receptor signalling on cognition-like, emotion-like and sociability behaviours of CCR6 and CCR7 knockout miceBehavioural Brain Research, 2014
- Chemokines in CNS injury and repairCell and tissue research, 2012
- Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairmentActa Neuropathologica, 2010
- Chemokine receptor expression by neural progenitor cells in neurogenic regions of mouse brainJournal of Comparative Neurology, 2006
- Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophilsJournal of Leukocyte Biology, 1997
- Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1Journal of Leukocyte Biology, 1996